You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

RAMIPRIL - Generic Drug Details

✉ Email this page to a colleague

What are the generic sources for ramipril and what is the scope of patent protection?

Ramipril is the generic ingredient in two branded drugs marketed by King Pharms Llc, Accord Hlthcare, Actavis Elizabeth, Aurobindo Pharma Ltd, Chartwell Molecular, Chartwell Rx, Cipla, Corepharma, Dr Reddys Labs Ltd, Hikma, Lupin, Ranbaxy Labs Ltd, Teva Pharms, Watson Labs, Zydus Pharms Usa, King Pfizer, Apotex, Natco Pharma, and Zydus Pharms Usa Inc, and is included in nineteen NDAs. Additional information is available in the individual branded drug profile pages.

There are nineteen drug master file entries for ramipril. Eighteen suppliers are listed for this compound.

Summary for RAMIPRIL

US Patents:	0
Tradenames:	2
Applicants:	19
NDAs:	19
Drug Master File Entries:	19
Finished Product Suppliers / Packagers:	18
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	169
Drug Prices:	Drug price trends for RAMIPRIL
Drug Sales Revenues:	Drug sales revenues for RAMIPRIL
What excipients (inactive ingredients) are in RAMIPRIL?	RAMIPRIL excipients list
DailyMed Link:	RAMIPRIL at DailyMed

See drug prices for RAMIPRIL

See drug sales revenues for RAMIPRIL

Recent Clinical Trials for RAMIPRIL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Menarini International Operations Luxembourg SA	Phase 4
John Paul II Hospital, Krakow	Phase 3
Ligand Research, LLC	Phase 1

See all RAMIPRIL clinical trials

Pharmacology for RAMIPRIL

Drug Class	Angiotensin Converting Enzyme Inhibitor
Mechanism of Action	Angiotensin-converting Enzyme Inhibitors

Medical Subject Heading (MeSH) Categories for RAMIPRIL

Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents

Anatomical Therapeutic Chemical (ATC) Classes for RAMIPRIL

C09AA	ACE inhibitors, plain
C09A	ACE INHIBITORS, PLAIN
C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
C	Cardiovascular system

US Patents and Regulatory Information for RAMIPRIL

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurobindo Pharma Ltd	RAMIPRIL	ramipril	CAPSULE;ORAL	091604-003	Jun 8, 2011	AB	RX	No	No	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
Zydus Pharms Usa Inc	RAMIPRIL	ramipril	TABLET;ORAL	090697-001	Sep 24, 2009		DISCN	No	No	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
Apotex	RAMIPRIL	ramipril	TABLET;ORAL	091069-003	Dec 2, 2015		DISCN	No	No	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for RAMIPRIL

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
King Pfizer	ALTACE	ramipril	TABLET;ORAL	022021-003	Feb 27, 2007	5,403,856	⤷ Subscribe
King Pharms Llc	ALTACE	ramipril	CAPSULE;ORAL	019901-003	Jan 28, 1991	5,061,722	⤷ Subscribe
King Pfizer	ALTACE	ramipril	TABLET;ORAL	022021-001	Feb 27, 2007	5,061,722	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

RAMIPRIL Market Analysis and Financial Projection Experimental

Ramipril Market Dynamics and Financial Trajectory

Market Overview

The ramipril market is experiencing significant growth, driven by several key factors. Ramipril, an angiotensin-converting enzyme (ACE) inhibitor, is widely used to treat conditions such as high blood pressure, heart failure, and diabetic kidney disease. Here’s a detailed look at the market dynamics and financial trajectory of ramipril.

Key Drivers

Rise in Cardiovascular Diseases

The increasing prevalence of cardiovascular diseases, including high blood pressure and hypertension, is a major driver for the ramipril market. As the global population ages and lifestyles become more sedentary, the incidence of these diseases is expected to rise, thereby boosting the demand for ramipril[2][3][4].

Advancements in Treatment

Improvements in the formulation of ramipril and the growing adoption of ACE inhibitors for chronic disorders are significant drivers. These advancements enhance the efficacy and safety of the drug, making it a preferred choice for managing cardiovascular conditions[2][3][4].

Growing Demand for Affordable Drugs

The increasing healthcare expenditure and the need for better, yet affordable, drugs are also driving the growth of the ramipril market. As healthcare costs rise, patients and healthcare providers seek effective and cost-efficient treatments, which ramipril often provides[2][3].

Market Size and Growth

The global ramipril market was valued at USD 550 million in 2021 and is projected to reach USD 729.86 million by 2029, growing at a Compound Annual Growth Rate (CAGR) of 3.6% during the forecast period of 2022 to 2029[2].

Segmentation

The ramipril market can be segmented based on several criteria:

By Product Type

Tablets
Capsules
Oral Solutions

These different forms cater to various patient needs and preferences, contributing to the market's growth[2][4].

By Indication

High Blood Pressure
Heart Failure
Diabetic Kidney Disease
Others

The versatility of ramipril in treating multiple conditions expands its market reach[2][3][4].

By Distribution Channel

Hospital Pharmacy
Online Pharmacy
Retail Pharmacy

The availability of ramipril through various distribution channels ensures widespread accessibility, further driving market growth[2][4].

Regional Landscape

North America

North America holds a significant share of the ramipril market due to the high prevalence of hypertension and heart-related diseases in the region. Government programs and investments in better cardiovascular disease therapies also contribute to the market's growth here[3][4].

Europe

Europe follows closely, driven by a well-established healthcare infrastructure and a large geriatric population. The region's strong healthcare system and high awareness about cardiovascular health support the demand for ramipril[4].

Asia Pacific

The Asia Pacific region is expected to witness substantial growth due to advancements in healthcare and increasing government initiatives. Rising awareness about cardiovascular health and improving access to healthcare facilities in this region are key factors driving the market[2][3][4].

Competitive Landscape

The ramipril market is highly competitive, with several major pharmaceutical companies vying for market share. Key players include:

Pfizer Inc.
Hikma Pharmaceuticals PLC
Teva Pharmaceutical Industries Ltd.
Dr. Reddy’s Laboratories Ltd
Novartis AG
Sanofi
Aurobindo Pharma Limited
Zydus Cadila
Lupin Pharmaceuticals, Inc.[1][3][4]

These companies focus on product development, strategic collaborations, and mergers to strengthen their market position and expand their product portfolios.

Opportunities and Challenges

Opportunities

Research and Development: Increased R&D on ramipril and expanding market regulations, along with financial donations from governing bodies, create new opportunities for market growth[1][2][3].
Emerging Markets: Untapped emerging markets offer significant growth opportunities for ramipril manufacturers to expand their market presence[4].
Combination Therapies: The trend towards combination therapies for hypertension management opens avenues for the development of fixed-dose combination products containing ramipril[4].

Challenges

Side Effects: The occurrence of side effects such as cough, dizziness, rectum bleeding, and stomach cramping can limit the adoption of ramipril and affect market growth[1][4].
Competition from Alternatives: The availability of alternative treatment options for hypertension and cardiovascular diseases poses a threat to the market growth of ramipril[4].
Stringent Regulatory Requirements: Compliance with regulatory standards and obtaining approvals for new formulations can pose challenges to manufacturers, impacting time-to-market[4].

Financial Trajectory

The financial trajectory of the ramipril market is positive, with steady growth anticipated over the forecast period. Here are some key financial highlights:

Market Size: The market is expected to grow from USD 550 million in 2021 to USD 729.86 million by 2029[2].
Revenue Generation: The increasing demand for ramipril translates into significant revenue generation for industry participants and stakeholders, enhancing their financial performance[4].
Investments in R&D: Pharmaceutical companies are investing heavily in research and development, which is expected to drive innovation and further growth in the market[1][2][3].

Key Takeaways

The ramipril market is driven by the increasing prevalence of cardiovascular diseases and advancements in treatment.
The market is segmented by product type, indication, and distribution channel, with North America, Europe, and Asia Pacific being major regions.
Key players are focusing on product development, strategic collaborations, and mergers to strengthen their market position.
Opportunities in emerging markets and combination therapies are expected to drive future growth.
Challenges include side effects, competition from alternatives, and stringent regulatory requirements.

FAQs

Q: What are the primary drivers of the ramipril market? A: The primary drivers include the rise in cardiovascular diseases, advancements in treatment, and the growing demand for affordable drugs.

Q: Which regions are expected to see significant growth in the ramipril market? A: North America, Europe, and Asia Pacific are expected to witness significant growth due to various factors such as high disease prevalence, advanced healthcare infrastructure, and government initiatives.

Q: Who are the key players in the ramipril market? A: Key players include Pfizer Inc., Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd, and others.

Q: What are the major challenges facing the ramipril market? A: The major challenges include side effects associated with the drug, competition from alternative treatments, and stringent regulatory requirements.

Q: What opportunities are available for the growth of the ramipril market? A: Opportunities include increased R&D, emerging markets, and the development of combination therapies.

Cited Sources

Allied Market Research - Ramipril Market Insight Data, Size, Industry Growth, 2030
Data Bridge Market Research - Ramipril Market Size, Scope & Growth Opportunities By 2029
BioSpace - Ramipril Market Market Outlook, Competitive Landscape ... - BioSpace
Market Wide Research - Ramipril Market 2024-2032 | Size, Share, Growth

More… ↓

⤷ Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.